EVolution Therapeutics is pleased to welcome PhD student Sasha Kieran for a three-month work experience placement as part of her MIBTP programme. During her time with the team, Sasha will support the development of our investor engagement strategy, helping to map and...
Exciting news from Evolution Therapeutics as we welcome Alice Wigington, who has joined the team as a Research Scientist. Alice is a first-class graduate of Aston University’s integrated master’s programme in Biological Sciences, bringing strong expertise in...
CEO of EVolution therapeutics, Dr James Gavin, was invited to present at the first-ever Midlands EV Network event. Here he shared his experience of co-founding EVolution Therapeutics, a company deeply rooted in the West Midlands and highlighted the tremendous...
We are delighted to announce that EVolution Therapeutics has secured a £284,000 Innovate UK grant to develop an advanced wound care therapeutic for the treatment of non-healing wounds. This funding was secured through participation in the BBSRC/Innovate UK innovation...
EVs are novel candidates for the delivery of bio-active molecules with their high bioavailability, intrinsic capability to cross biological barriers and remarkable biocompatibility. Our cutting-edge research has the potential to develop the next generation of...
